Monoclonal antibody (mAb) product innovation aim of facility expansion in KansasAugust 23, 2024A $130-million investment through 2026 is expected to bolster production and development of monoclonal antibody-based therapy, including a potential product in canine dermatology.
SPONSORED CONTENTA Modern Approach to Parasite PreventionWith evolving parasite threats, traditional preventatives may not be enough. Discover how innovation is changing the landscape of protection. + Learn More